The next-gen serum addresses common pigmentation concerns such as melasma, uneven skin tone, dark spots, and post inflammatory hyperpigmentation
Emcutix Biopharmaceuticals, a dermatology-focussed and wholly owned subsidiary of Emcure Pharmaceuticals, announced the launch of SOLGLO-AZ Liposomal Serum, a unique combination powered by Lipotwin Technology and Hyperboost Brightening Complex. Crafted specially for Indian skin, this next-gen serum addresses common pigmentation concerns such as melasma, uneven skin tone, dark spots, and post inflammatory hyperpigmentation (PIH).
At the core of the innovation is Lipotwin Technology, which encapsulates both Azelaic Acid and 4-n-Butylresorcinol in dual-liposomal system. Liposomes are microscopic, skin-compatible lipid vesicles that mimic the skin’s natural lipid structure. By fusing seamlessly with the skin barrier and transporting actives beyond the surface, they enable enhanced penetration and reduced irritation, improved tolerability and better performance in persistent pigmentation concerns such as melasma and Post-inflammatory hyperpigmentation.
“Hyperpigmentation affects large number of people and often leads them to explore solutions that help them feel comfortable and confident in their skin,” said Biswarup Chatterjee, VP – Sales, Emcutix Biopharmaceuticals Ltd. “With an advanced liposomal approach and clinically recognised ingredients, we aim to equip dermatologists with a solution that supports clearer, healthier-looking skin over time.”
Dermatologically tested, non-comedogenic, and clinically assessed on Indian skin, SOLGLO-AZ ensures reduced irritation and better patient compliance. Its formulation is suitable for daily use, helping deliver a clearer, brighter, and more even complexion.
